Companies Cryptocurrencies
Neoleukin Therapeutics Inc
Neoleukin Therapeutics Inc
Exchange: NasdaqGM
IPO Date: 12/03/2014
CEO: Dr. Jonathan Drachman
Drug Manufacturers General Specialty & Generic Healthcare 🔗
  • NLTX
  • 7.27
  • 308430464
    market cap
  • -0.40999985
If you bought

shares of Neoleukin Therapeutics Inc (NLTX) on
You would have made
Old Price $12 Current Price $12

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The company is headquartered in Seattle, Washington and currently employs 8 full-time employees. The firm is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.

Address: 1616 Eastlake Ave E Ste 360 Seattle WASHINGTON 98102

Stay updated.